Each step. Every patient. Exactly what you need.
The MyRisk® Hereditary Cancer Test, combined with Myriad’s industry-leading Variant Classification Program, utilizes RNA testing strategically, along with other proprietary tools, to deliver highly accurate variant interpretations, ensuring precise and actionable results for more patients, without unnecessary testing.1,2
While others leave you guessing, MyRisk delivers clarity, with the industry’s lowest reported VUS rate for BRCA1/2 of 1.0%.1,2 Get more definitive results for more patients—don’t settle for less.
RNA analysis works by complementing DNA analysis to show how genetic variants impact splicing, revealing whether a gene produces normal or abnormal transcripts, or a mixture of the two. But not all patients benefit from RNA analysis, and not all labs offer a personalized approach to RNA testing.
Superior baseline DNA analysis: The MyRisk® Test identifies and classifies most variants that could influence splicing via its DNA analysis that includes exons and extends into the introns of each gene. Because of Myriad’s superior variant classification tools, most variants can be classified confidently without the need for RNA analysis.
Targeted RNA analysis for maximum impact: Unlike competitors who apply RNA testing across all cases, the MyRisk Test strategically utilizes RNA analysis to resolve specific VUS cases, helping to avoid unnecessary testing while allowing for precise classifications.
No additional cost for RNA testing: Myriad proactively works with the ordering clinician and the patient when a variant is found that may benefit from RNA analysis. In our process, if RNA testing is appropriate, the additional analysis of the variant is done at no additional cost, often without the need for a re-draw.3 This ensures clinicians receive the most meaningful insights without additional financial burden for the patient.
While other labs rely on upfront paired DNA/RNA testing to compensate for weaker variant classification via DNA analysis, The MyRisk Test already classifies most variants through its superior DNA analysis.
This deep baseline analysis helps optimize the use of reflex testing.
of potential splicing variants occur within the DNA regions analyzed on MyRisk4
Whenever the MyRisk Test detects a new potential splicing variant through DNA sequencing, Myriad carefully investigates the relevance of further RNA analysis. MyRisk utilizes RNA analysis only on variants where RNA data could be the determining factor in a pathogenic classification. When RNA analysis is performed, our methodology allows us to classify splicing variants with exceptional precision.
Standard RNA sequencing methods used by some labs may produce false-positive classifications by detecting aberrant transcripts while failing to recognize the presence of normal transcripts, mistakenly classifying a variant as pathogenic.5 The MyRisk Test incorporates allele-specific quantification, which identifies whether a variant allele produces both normal and aberrant transcripts—a level of precision that helps avoid false-positive classifications that could mislead clinical decisions.5
In addition, the targeted approach of the MyRisk test optimizes cost efficiency by applying RNA analysis only to VUSs where it can change the classification. This ensures that unnecessary testing does not inflate healthcare expenses while maintaining the highest level of diagnostic accuracy.
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
MyRisk is a powerful tool that empowers you to make more informed decisions for your high-risk unaffected patients and your patients diagnosed with cancer throughout their care journey.